- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
- Imlunestrant: MedlinePlus Drug Information
Imlunestrant is used to treat certain types of breast cancer Imlunestrant is in a class of medications called estrogen receptor antagonists It works by helping to stop tumor growth
- HCP Home | Inluriyo™ (imlunestrant)
Imlunestrant inhibits both P-gp and BCRP Avoid concomitant use unless otherwise recommended in the Prescribing Information for P-gp or BCRP substrates where minimal concentration changes may lead to serious adverse reactions
- FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated . . .
On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with ER-positive, HER2-negative,
- Imlunestrant - Wikipedia
Imlunestrant, sold under the brand name Inluriyo, is an anti-cancer medication used for the treatment of breast cancer [1] It is an estrogen receptor antagonist [1]
- FDA Approves Imlunestrant (Inluriyo) for Breast Cancer
Imlunestrant is a hormonal therapy medicine used to treat advanced-stage hormone receptor-positive breast cancer that grew during treatment with other hormonal therapy medicines
- Uses, Side Effects Warnings - Drugs. com
: side effects, dosage, interactions, FAQs, reviews Used for: breast cancer
- FDA Approves Imlunestrant to Stop Progression of ER+, HER2-, ESR1 . . .
The drug, imlunestrant (Inluriyo), is approved for people with ER-positive, HER2-negative advanced or metastatic breast cancer that has an ESR1 mutation who had previously been treated with hormone therapy
|